Lack of prophylactic effect of incadronate on skeletal lesions associated with implants of prostate cancer.
OBJECTIVE
To evaluate prophylactic effects of bisphosphonate (BP) on skeletal lesions induced by prostate cancer (CaP).


METHODS
Incadronate, a third-generation BP, was administered weekly for 4 weeks, with or without 4-week pre-administration, to rats whose calvaria had been inoculated with syngeneic CaP tissue.


RESULTS
The transplanted CaP grew up and caused bone resorption with osteoblastic changes regardless of incadronate treatment. Although decrease in bone resorption accompanied by reduced number of osteoclasts was shown by incadronate administration, pre-administration had no additional inhibitory effect on bone destruction and Ki-67 labeling indices of CaP cells were not altered.


CONCLUSIONS
These results indicate that application of BP alone is not sufficient to prevent skeletal lesions due to CaP in patients with high risk of bone metastases although it is useful in inhibition of cancer-induced bone resorption with osteoblastic changes.
Hikosaka
Atsuya
A
Department of Experimental Pathology and Tumor Biology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, 467-8601, Japan. uropatho@ybb.ne.jp
Futakuchi
Mitsuru
M
Ogiso
Tadashi
T
Suzuki
Shugo
S
Kohri
Kenjiro
K
Shirai
Tomoyuki
T
D000818:Animals; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000517:prevention & control* / Q000556:secondary*; D004164:Diphosphonates / Q000627:therapeutic use*; D008297:Male; D009368:Neoplasm Transplantation; D011471:Prostatic Neoplasms / Q000473:pathology*; D051381:Rats; D011916:Rats, Inbred F344; D017211:Treatment Failure
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; C071542:cimadronate